Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala. In this segment, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, provides a corporate update highlighting the Company’s progress in 2025, key ...

In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will pr ...

Core Viewpoint - Akari Therapeutics has made significant progress in 2025 towards developing best-in-class antibody drug conjugates (ADCs) with a novel payload, positioning the company for a pivotal year ahead in 2026 [1][12]. Group 1: Scientific Advancements - Akari has established a clear scientific roadmap focused on its proprietary PH1 payload, which is designed to overcome limitations of existing ADC payloads by directly killing cancer cells and engaging the immune system [2][4]. - The lead program, AKTX-101, is a Trop2 targeted ADC that utilizes the PH1 payload and has shown significant preclinical activity against various cancers, including pancreatic and prostate cancers [6][17]. - The partnership with WuXi XDC for GMP-grade clinical product manufacturing is a critical milestone that supports the upcoming Phase 1 clinical trials for AKTX-101 [4][7]. Group 2: Intellectual Property and Engagement - Akari has strengthened its intellectual property portfolio with new provisional patent filings related to the PH1 payload, enhancing the value of its ADC platform [8]. - Promising immuno-oncology data was presented at the Society for Immunotherapy Cancer (SITC), generating enthusiasm among researchers and scientists regarding the unique approach of splicing modulation via the PH1 payload [9]. Group 3: Operational and Financial Strategy - The company has taken steps to strengthen its operating model and capital discipline, enabling R&D milestones and key patent filings while reducing operating expenses post-merger [11]. - Akari is positioned to pursue additional financing and partnership opportunities with strategic investors and pharmaceutical companies, leveraging upcoming catalysts and milestones with AKTX-101 [11]. Group 4: Future Outlook - 2026 is anticipated to be a transformational year for Akari, with key milestones including the initiation of Phase 1 clinical studies, regulatory interactions with the FDA, and continued partnership discussions [12][15]. - The transition from a preclinical discovery company to a clinical-focused biotechnology player is expected to enhance visibility and investor interest [13][14].

Core Viewpoint - Akari Therapeutics has announced a definitive agreement for the issuance and sale of approximately 12.6 million American Depositary Shares (ADSs) and unregistered warrants, with significant participation from its Directors, Officers, and Executive Management, aimed at supporting its oncology drug development initiatives and improving its capital structure [1][4][6]. Group 1: Offering Details - The offering includes 10,043,774 ADSs in a registered direct offering priced at $0.3883 per ADS, along with unregistered Series G warrants [3]. - A concurrent private placement will issue unregistered pre-funded warrants for 2,563,713 ADSs at a combined price of $0.4041 per ADS [3]. - The gross proceeds from the offering are expected to be around $5 million, with over $1 million coming from new cash investments by the Company's Directors, Officers, and Executive Management [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for ongoing research and development, working capital, and general corporate purposes [4]. Group 3: Debt Conversion - Existing note holders have agreed to convert approximately $2.5 million of the Company's outstanding debt into unregistered pre-funded warrants and warrants to purchase 6,409,410 ADSs at a combined exchange price of $0.4041 per ADS [5]. Group 4: Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs), with its lead candidate AKTX-101 targeting the Trop2 receptor on cancer cells [10]. - The novel payload PH1 is designed to disrupt RNA splicing within cancer cells, showing significant activity and prolonged survival in preclinical studies compared to traditional ADCs [10].

Core Insights - Akari Therapeutics is advancing a new class of immuno-oncology antibody drug conjugates (ADCs) utilizing a novel PH1 payload designed to target and disrupt the spliceosome, showing promising preclinical efficacy and safety profiles [3][4] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and is set to enter IND-enabling studies with plans for clinical trials in Q4 2026 [3][4] Company Overview - Akari Therapeutics specializes in developing next-generation spliceosome payload ADCs, differentiating itself from traditional ADCs that use tubulin inhibitors and DNA damaging agents [4] - The PH1 payload is a spliceosome modulator that disrupts RNA splicing in cancer cells, leading to cancer cell death and activation of immune responses [4] Product Development - AKTX-101 has demonstrated significant activity and prolonged survival in preclinical studies compared to traditional ADCs, with potential for synergy with checkpoint inhibitors [4] - The company is generating validating data on the PH1 payload to advance AKTX-101 and explore other undisclosed targets [4]

Core Insights - Akari Therapeutics is focused on developing novel payloads for antibody drug conjugates (ADCs), specifically highlighting its innovative PH1 payload and its dual mechanism of action [1][3] - The company aims to advance differentiated therapies for oncology patients through its next-generation ADC discovery platform [1][3] Company Overview - Akari Therapeutics is an oncology biotechnology company that specializes in next-generation spliceosome payload ADCs [3] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [3] Product Innovation - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, which has shown potential to induce cancer cell death and activate immune responses [3] - Preclinical studies of AKTX-101, an ADC utilizing the PH1 payload, have demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - AKTX-101 has shown potential synergy with checkpoint inhibitors, exhibiting prolonged survival both as a single agent and in combination with these inhibitors [3]

Core Insights - The novel spliceosome targeting payload, PH1, shows potential in inducing cancer cell cytotoxicity and activating anti-tumor immunity through various mechanisms [1][3] - The combination of Trastuzumab-PH1 ADC with anti-PD1 therapy significantly outperforms Kadcyla® with anti-PD1 in achieving complete tumor regressions (74% vs. 42%, p<0.05) [1][12] - Akari Therapeutics is advancing its lead ADC candidate, AKTX-101, which targets the Trop2 receptor and utilizes the PH1 payload, aiming to enter clinical trials soon [7][9] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [9] - The company’s innovative ADC platform allows for the generation and optimization of ADC candidates tailored to specific targets [9] - The PH1 payload is designed to disrupt RNA splicing in cancer cells, leading to cancer cell death and immune activation [9] Mechanism of Action - Trastuzumab-PH1 induces RNA mis-splicing, resulting in increased neoantigen generation and a subsequent rise in anti-cancer immune cells within the tumor microenvironment [4][12] - The combination therapy enhances immune responses, including the polarization of macrophages, increase in neutrophils, and expansion of B cell clones producing IgM antibodies [3][12] - The synergy between Trastuzumab PH1 and anti-PD1 therapy is attributed to their complementary effects on the immune system, particularly the expansion of gamma-delta T cell clones [3][12] Market Potential - The immuno-oncology therapeutic class is currently valued at approximately $50 billion per year, with the potential for significant growth through innovative therapies like those developed by Akari [1][4] - The unique results from the Trastuzumab-PH1 and anti-PD1 combination therapy could establish a new standard of care in cancer treatment, improving patient outcomes [6][12] Upcoming Events - Akari Therapeutics will host a live webcast on November 18, 2025, to discuss the presented data, providing insights for investors and analysts [1][8]

Core Insights - Akari Therapeutics is presenting data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting, highlighting its immune mechanism-of-action and potential in oncology [1][2] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5][6] - The PH1 payload is designed to disrupt RNA splicing within cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune cells [5][6] Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2] - The immune response stimulated by the PH1 ADC is attributed to neoantigen activation, which enhances the activity of antigen-presenting cells, B, and T-cells [2] - Notably, the combination of PH1 ADC and anti-PD-1 expanded the population of gamma-delta T cells, which are effective in tumor killing [2] Presentation Details - The oral and poster presentations will take place on November 7 and 9, 2025, at the Gaylord National Resort and Convention Center, with specific times and locations provided for attendees [3][4]

Core Insights - Akari Therapeutics is presenting new data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual SITC Meeting, highlighting its immune mechanism-of-action and potential in oncology treatment [1][2]. Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5]. - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune responses [5]. Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2]. - The immune response stimulated by the PH1 ADC involves neoantigen activation, antigen-presenting cells, and T-cell activation, leading to enhanced therapeutic potential [2]. Presentation Details - The oral and poster presentations will provide further insights into the findings, with specific sessions scheduled for November 7 and November 9, 2025 [3][4].

Core Insights - Akari Therapeutics has launched a new platform called CEO Corner, aimed at providing deeper insights into the company's press releases, corporate developments, and pipeline progress [2][3] - The CEO Corner will allow stakeholders to ask questions and suggest topics for future discussions, enhancing engagement and transparency [1][2] Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) for oncology applications [4] - The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver a novel PH1 payload directly into tumors [4] - PH1 is designed to modulate RNA splicing within cancer cells, leading to cancer cell death and activation of immune responses, showing significant activity in preclinical studies compared to traditional ADCs [4] Product Development - AKTX-101 has demonstrated prolonged survival in preclinical models, both as a single agent and in combination with checkpoint inhibitors, indicating its potential for synergistic effects [4] - The company is actively generating validating data on the PH1 payload to further advance AKTX-101 and explore other undisclosed targets [4]